Abnormal uterine and vaginal bleeding. Other abnormal uterine and vaginal bleeding
Conditions
Interventions
Intervention 1: Intervention group 1 : A 100 mg capsule of natural micronized progesterone called Utrogestan will be used, starting from the first day of the period for 30 days, two capsules of 200 mg
Treatment - Drugs
Intervention group 1 : A 100 mg capsule of natural micronized progesterone called Utrogestan will be used, starting from the first day of the period for 30 days, two capsules of 200 mg will be used at
Intervention group 2: Intramuscular injection of 3.75 mg of diafililic ampoule as a GnRH agonist compound will be used on day 21 of the period two dose intervals of 28 days for 2 months prior to the h
Sponsors
Vice chancellor for Research,Tabriz University Of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients with abnormal uterine bleeding Patients with submucosal myoma with a diameter of 30 mm or less and zero or first grade
Exclusion criteria
Exclusion criteria: : Patients with a history of heart disease; Hepatic; Diabetes; Thromboembolism; Cancer of the uterus and cervix; Submucosal leiomyoma larger than 3 cm; Uterine septum; pregnant women; Severe bleeding; Anti coagulation therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The hemoglobin concentration. Timepoint: Six hours after surgery. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of surgery. Timepoint: After surgery. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehri Jaefari Shobeiri
Tabriz University of Medical Sciences
Outcome results
None listed